<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Neonc Technologies Holdings, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock</link>
    <description>Latest news and press releases for Neonc Technologies Holdings, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 18 May 2026 13:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/neonc-technologies-holdings-inc-common-stock" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a3d478dffbe2df10a61d.webp</url>
      <title>Neonc Technologies Holdings, Inc.</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock</link>
    </image>
    <item>
      <title>NeOnc Provides Business Update and Reports Q1 2026 Financial Results</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-provides-business-update-and-reports-q1-2026-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-provides-business-update-and-reports-q1-2026-financial-results</guid>
      <pubDate>Mon, 18 May 2026 13:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: “The f</description>
    </item>
    <item>
      <title>NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-ceo-accelerates-insider-buying-with-dollar500k-investment-ahead-of-imminent-neo100-phase-2a-data-catalysts</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-ceo-accelerates-insider-buying-with-dollar500k-investment-ahead-of-imminent-neo100-phase-2a-data-catalysts</guid>
      <pubDate>Tue, 05 May 2026 13:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring s</description>
    </item>
    <item>
      <title>NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-holdings-inc-announces-dollar300000-in-insider-purchases-of-nthi-stock-by-chairman-and-ceo-company-provides-context-on-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-holdings-inc-announces-dollar300000-in-insider-purchases-of-nthi-stock-by-chairman-and-ceo-company-provides-context-on-2025-financial-results</guid>
      <pubDate>Tue, 14 Apr 2026 13:00:00 GMT</pubDate>
      <description>Insider buying indicates management&apos;s conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout - expected within ~4 months NEO212: expects Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study - within the next 4 weeks CALABASAS, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (“NTHI” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapie</description>
    </item>
    <item>
      <title>NeOnc Provides Business Update and Reports Q4 2025 Financial Results</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-provides-business-update-and-reports-q4-2025-financial-results-5</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-provides-business-update-and-reports-q4-2025-financial-results-5</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2</description>
    </item>
    <item>
      <title>NeOnc Technologies Appoints David Choi as Chief Accounting Officer</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-appoints-david-choi-as-chief-accounting-officer-536</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-appoints-david-choi-as-chief-accounting-officer-536</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2</description>
    </item>
    <item>
      <title>NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-reports-phase-1-dose-escalation-results-for-dosing-and-toxicity-and-determination-of-recommended-phase-2-dose-for-oral-neo212-management-to-host-kol-conference-call-today-at-9-am-et-15</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-reports-phase-1-dose-escalation-results-for-dosing-and-toxicity-and-determination-of-recommended-phase-2-dose-for-oral-neo212-management-to-host-kol-conference-call-today-at-9-am-et-15</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2</description>
    </item>
    <item>
      <title>NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-nasdaq-nthi-to-host-investor-conference-call-to-present-dose-escalation-results-from-full-phase-1-neo212-01-readout-for-dosing-and-toxicity</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-nasdaq-nthi-to-host-investor-conference-call-to-present-dose-escalation-results-from-full-phase-1-neo212-01-readout-for-dosing-and-toxicity</guid>
      <pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2</description>
    </item>
    <item>
      <title>NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-secures-strategic-pipe-140000004</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-secures-strategic-pipe-140000004</guid>
      <pubDate>Fri, 30 Jan 2026 14:00:00 GMT</pubDate>
      <description>Investment led by Cinctive Co-Founder Richard Schimel underscores institutional confidence in NeOnc’s biotech pipelineCALABASAS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity (&quot;PIPE&quot;) fo</description>
    </item>
    <item>
      <title>Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/stonegate-capital-partners-initiates-coverage-003200149</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/stonegate-capital-partners-initiates-coverage-003200149</guid>
      <pubDate>Sat, 10 Jan 2026 00:32:00 GMT</pubDate>
      <description>Dallas, Texas--(Newsfile Corp. - January 9, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners initiates their coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company developing central nervous system therapeutics designed to overcome the blood-brain barrier. The Company has numerous assets in its pipeline, highlighted by NEO100 which is a patented, pure pharmaceutical...</description>
    </item>
    <item>
      <title>NeOnc Technologies Reports Updated Clinical Results</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-reports-updated-clinical-140000614</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-reports-updated-clinical-140000614</guid>
      <pubDate>Mon, 15 Dec 2025 14:00:00 GMT</pubDate>
      <description>Expanded Clinical Experience Demonstrates Additional Long-Term Survival and Radiographic Remission in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100CALABASAS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced updated clinical results from its ongoing Phase 1</description>
    </item>
    <item>
      <title>NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-nasdaq-nthi-announces-140000206</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-nasdaq-nthi-announces-140000206</guid>
      <pubDate>Mon, 01 Dec 2025 14:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today announced newly published preclinical findings from a research collaboration at the University of Southern California (USC). The study, now available on bioRxiv (https://www.biorxiv.org/content/10.1101/2025.11.25.690556v1), demonstrates that ultrasound further enhan</description>
    </item>
    <item>
      <title>NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-holdings-reports-third-210100718</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-holdings-reports-third-210100718</guid>
      <pubDate>Fri, 14 Nov 2025 21:01:00 GMT</pubDate>
      <description>CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter &amp; Recent Corporate Highlights Middle East – NuroMENA, the UAE-based subsidiary, advan</description>
    </item>
    <item>
      <title>NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-completes-enrollment-pivotal-140000496</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-completes-enrollment-pivotal-140000496</guid>
      <pubDate>Thu, 13 Nov 2025 14:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial. The trial is evaluating the company’s lead therapeutic candidate, NEO100, for the treatment of recurrent isocitrate dehydrogenase 1 (IDH1)–muta</description>
    </item>
    <item>
      <title>NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-nasdaq-nthi-host-140000182</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-nasdaq-nthi-host-140000182</guid>
      <pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open). During the call, membe</description>
    </item>
    <item>
      <title>NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-appoints-amir-heshmatpour-140000436</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-appoints-amir-heshmatpour-140000436</guid>
      <pubDate>Tue, 04 Nov 2025 14:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Boa</description>
    </item>
    <item>
      <title>His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies&apos; Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/highness-sheikh-nahyan-bin-zayed-130000976</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/highness-sheikh-nahyan-bin-zayed-130000976</guid>
      <pubDate>Tue, 28 Oct 2025 13:00:00 GMT</pubDate>
      <description>CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, announces a landmark development for global healthcare innovation, His Highness Sheikh Nahyan bin Zayed Al Nahyan, Chairman of the Zayed Charitable and Humanitarian Foundation, will formally assume the role of Executive Ch</description>
    </item>
    <item>
      <title>Meet the Companies - New to The Street&apos;s Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/meet-the-companies-new-to-the-streets-accredited-investor-event-returns-october-21-22-at-hudson-yards-nyc-3</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/meet-the-companies-new-to-the-streets-accredited-investor-event-returns-october-21-22-at-hudson-yards-nyc-3</guid>
      <pubDate>Fri, 10 Oct 2025 19:35:00 GMT</pubDate>
      <description>NEW YORK CITY, NEW YORK / ACCESS Newswire / October 10, 2025 /New to The Street, one of the nation&apos;s longest-running business television brands airing as sponsored programming on Fox Business and Bloomberg, announces its upcoming &quot;Meet the Companies&quot; ...</description>
    </item>
    <item>
      <title>NeOnc Technologies&apos; Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-subsidiary-nuromena-signs-130000014</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-subsidiary-nuromena-signs-130000014</guid>
      <pubDate>Thu, 09 Oct 2025 13:00:00 GMT</pubDate>
      <description>CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Orga</description>
    </item>
    <item>
      <title>NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-quazar-investment-set-130000126</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-quazar-investment-set-130000126</guid>
      <pubDate>Mon, 06 Oct 2025 13:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced a significant milestone in its partnership with Quazar Investment. Following the receipt of all necessary tax identification and regulatory approvals from the United Arab Emirates (UAE), the closing of the previously announced $50 million str</description>
    </item>
    <item>
      <title>NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board</title>
      <link>https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-appoints-dr-david-130000554</link>
      <guid isPermaLink="true">https://6ix.com/company/neonc-technologies-holdings-inc-common-stock/news/neonc-technologies-appoints-dr-david-130000554</guid>
      <pubDate>Thu, 02 Oct 2025 13:00:00 GMT</pubDate>
      <description>CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F.</description>
    </item>
  </channel>
</rss>